Announcements Trials
Browse Landscape

Phase

Phase NA 12Phase 4 7Phase 3 5Phase 1/2 4Phase 2/3 2Phase 2 2Phase EARLY_PHASE1 1

Status

Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pleural Effusion, Malignant 1

Interventions

fludarabine 17Cyclophosphamide 16Positron Emission Tomography Computed Tomography 4Oncolytic Virotherapy 4Metformin 468Ga-pentixafor 4lenvatinib 3Radiosurgery 3Pemetrexed 3Paclitaxel 3Melphalan 3Immunotherapy, Adoptive 3Gemcitabine 3Cholestanetriol 26-Monooxygenase 3Carboplatin 3toripalimab 2sintilimab 2pembrolizumab 2gallium Ga 68 dotatate 2gallium 68 PSMA-11 2fludarabine phosphate 2alpha-Synuclein 2Progesterone 2Nivolumab 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Influenza Vaccines 2Fluorodeoxyglucose F18 2Ethiodized Oil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Unknown × Sodium Chloride × Clear all
NCT05565014 2022-10-04

Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion

Hubei Cancer Hospital

Phase EARLY_PHASE1 Unknown
90 enrolled
Thoracic

Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡